Astrazeneca Plc ADR (AZN)

$193.03 +5.87 (3.14%)
Market Cap 290.72B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 20.17
Forward PE 17.99
Profit Margin 13.01%
Debt to Equity Ratio 0.67
Volume 3,116,567
Avg Vol 6,638,534
Day's Range N/A - N/A
Shares Out 1.55B
Stochastic %K 94%
Beta 0.34
Analysts Strong Sell
Price Target $204.33

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
ZacksResearch
ZacksResearch Mar. 16 at 2:58 PM
$LLY could reportedly re-enter the bidding race for $ABVX if $AZN fails to submit an acquisition offer before the March 23 exclusivity deadline 👀 Reports indicate AstraZeneca currently has exclusive access to Abivax’s data room as it evaluates a potential takeover of the French biotech, whose shares skyrocketed last year after strong Phase 3 data for ulcerative colitis drug candidate obefazimod. If the exclusivity window closes without a bid, Lilly could re-engage as Big Pharma continues hunting for late-stage pipeline assets 💊 📊 Price target breakdown here👇 https://www.zacks.com/stock/research/LLY/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-37316&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_37316
0 · Reply
briefingcom
briefingcom Mar. 16 at 12:35 PM
$AZN: AstraZeneca receives EU approval for Imfinzi in early gastric and gastroesophageal cancers https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260316042755AZN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Quantumup
Quantumup Mar. 16 at 11:16 AM
Jefferies🏁 $ABVX at a Buy rating and a $160 PT. $AZN $LLY ABBV PFE $PTGX - $JNJ Jefferies said in its initiation report: Obe already looks like a real and differentiated UC drug, and we think the 2Q26 maintenance readout is fairly de-risked and should provide clear path to approval. We also think Crohn's matters for the long-term valuation (and hence any potl strategic interest). We are more bullish vs buyside expectations and see a strong shot based on MOA, translational data, and precedent. Bottom line: ABVX still underappreciated relative to the robust UC story and CD upside.
0 · Reply
Quantumup
Quantumup Mar. 13 at 3:09 PM
BofA⬆️ Mineralys' PT to $51 from $46 and reiterated at a Buy, separately Stifel on $MLYS said: We reiterate our Buy rating, $52 TP. $AZN $ALNY - $RHHBY $NVS Here's what else Stifel had to say: https://x.com/Quantumup1/status/2032473479035936901?s=20
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:37 PM
$AZN take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
Chipwars
Chipwars Mar. 12 at 3:50 PM
$AZN AstraZeneca (AZN) Refutes Takeover Speculation https://www.gurufocus.com/news/8703449/astrazeneca-azn-refutes-takeover-speculation
0 · Reply
Quantumup
Quantumup Mar. 12 at 2:55 PM
Cantor reiterated $CMPX at an Overweight rating, and said: In April, we expect the long-awaited PFS/OS readout from the Phase 2/3 COMPANION-002 trial of tovecimig (DLL4 x VEGF-A) in second-line biliary tract cancer (BTC). $AZN $MRK PFE RLAY Cantor added—This represents a high-stakes readout for Compass and one we view with cautious optimism. In this note, we walk through trial background, expectations for PFS and OS, potential stock scenarios, and key risks. We believe the trial is highly likely to achieve statistical significance on PFS, broadly in line with investor expectations. The core debate centers on overall survival (OS) and whether the study will clear the statistical threshold on this secondary endpoint. Given that ~80% OS events were triggered in 1Q26, in-line with our assumptions in our initiation report, we maintain our ~50% probability of success for OS.
0 · Reply
Chipwars
Chipwars Mar. 12 at 2:30 PM
$AZN AstraZeneca ranks among the 14 safe stocks to buy now for a starter stock portfolio. https://finance.yahoo.com/news/morgan-stanley-sees-double-digit-063059179.html
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 12 at 12:33 PM
$ABVX (+9.3% pre) The French start-up led by Marc de Garidel is giving the British pharma giant $AZN exclusive access to its data until 23 March to help it decide on its takeover bid. If it fails to make a bid by that date, Abivax will be free to negotiate with other potential buyers. - La Lettre https://ooc.bz/l/96438
1 · Reply
notreload_ai
notreload_ai Mar. 12 at 11:42 AM
$ABVX , $AZN, $LLY ... AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise. https://notreload.xyz/astrazeneca-leads-abivax-takeover-talks-until-march-23/
0 · Reply
Latest News on AZN
AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer

Mon, 16 Mar 2026 02:58:00 -0400 - 10 hours ago

AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer

Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report

2026-03-12T15:57:34.000Z - 4 days ago

Abivax (ABVX) Shares Surge Amid Denial of AstraZeneca Takeover Report

AZN Stock Experiences Slight Dip in Morning Trading

2026-03-12T15:51:09.000Z - 4 days ago

AZN Stock Experiences Slight Dip in Morning Trading

AstraZeneca (AZN) Refutes Takeover Speculation

2026-03-12T15:27:09.000Z - 4 days ago

AstraZeneca (AZN) Refutes Takeover Speculation

AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax

2026-03-12T11:25:57.000Z - 4 days ago

AstraZeneca (AZN) Obtains Exclusive Negotiation Period with Abivax

AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax

2026-03-12T11:25:29.000Z - 4 days ago

AstraZeneca (AZN) Engages in Exclusive Takeover Talks with Abivax

AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares

2026-03-12T11:25:17.000Z - 4 days ago

AstraZeneca (AZN) Enters Exclusive Agreement Boosting Abivax Shares

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

Thu, 12 Mar 2026 06:46:52 -0400 - 4 days ago

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

2026-03-12T10:46:52.000Z - 4 days ago

Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline

Health Rounds: Death from dementia on the rise among people with type 2 diabetes

Wed, 11 Mar 2026 07:28:05 -0400 - 5 days ago

Health Rounds: Death from dementia on the rise among people with type 2 diabetes

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

Tue, 10 Mar 2026 08:30:00 -0400 - 6 days ago

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

2026-03-10T10:53:48.000Z - 6 days ago

Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

AstraZeneca Announces Approval Of Koselugo In Canada

2026-03-09T12:41:09.000Z - 7 days ago

AstraZeneca Announces Approval Of Koselugo In Canada

AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment

2026-03-09T10:25:19.000Z - 7 days ago

AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment

Daiichi Sankyo: FDA Grants Priority Review For ENHERTU

2026-03-09T07:01:50.000Z - 7 days ago

Daiichi Sankyo: FDA Grants Priority Review For ENHERTU

AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns

2026-03-08T22:25:21.000Z - 7 days ago

AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns

The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop

2026-03-06T10:22:00.000Z - 10 days ago

The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop

Pay bonanza for blue chip bosses: Rolls-Royce chief 'Turbo' Tufan set for £24m as GSK's Walmsley scoops £15.7m

2026-03-05T22:00:12.000Z - 10 days ago

Pay bonanza for blue chip bosses: Rolls-Royce chief 'Turbo' Tufan set for £24m as GSK's Walmsley scoops £15.7m

Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca

2026-03-05T21:31:00.000Z - 10 days ago

Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca

Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor

2026-03-05T11:00:24.000Z - 11 days ago

Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor

GLP-1 drugs protect against new or worsening addictions, large study shows

Wed, 04 Mar 2026 18:36:07 -0500 - 11 days ago

GLP-1 drugs protect against new or worsening addictions, large study shows

AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Investment Horizons

2026-03-04T13:50:35.000Z - 12 days ago

AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Investment Horizons

If You Invested $100 In AstraZeneca Stock 5 Years Ago, You Would Have This Much Today

2026-02-27T15:30:56.000Z - 17 days ago

If You Invested $100 In AstraZeneca Stock 5 Years Ago, You Would Have This Much Today

Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades

Fri, 27 Feb 2026 06:50:00 -0500 - 17 days ago

Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades

AstraZeneca Prices $2 Bln Three Tranche Bond Offering

2026-02-26T07:56:04.000Z - 18 days ago

AstraZeneca Prices $2 Bln Three Tranche Bond Offering

AstraZeneca Launches “A.Catalyst Thailand Hub”: AI-Integrated Health Transformation

2026-02-26T01:00:00.000Z - 18 days ago

AstraZeneca Launches “A.Catalyst Thailand Hub”: AI-Integrated Health Transformation

The £168MILLION man: That's how much AstraZeneca boss Pascal Soriot has been paid in 14 years at the top

2026-02-24T22:03:08.000Z - 19 days ago

The £168MILLION man: That's how much AstraZeneca boss Pascal Soriot has been paid in 14 years at the top

AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025

2026-02-24T16:50:20.000Z - 20 days ago

AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

Tue, 24 Feb 2026 06:33:39 -0500 - 20 days ago

AstraZeneca boosts CEO Soriot's pay to about $24 million for 2025

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

2026-02-23T13:55:00.000Z - 21 days ago

AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer

AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment

2026-02-20T17:29:16.000Z - 24 days ago

AstraZeneca (AZN) Gains FDA Orphan Designation for Follicular Lymphoma Treatment

FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer

2026-02-20T13:02:32.000Z - 24 days ago

FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer

AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment

2026-02-20T12:28:10.000Z - 24 days ago

AstraZeneca's (AZN) Calquence Gains FDA Approval for New Leukemia Treatment

CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

2026-02-20T12:00:00.000Z - 24 days ago

CALQUENCE plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment

2026-02-20T11:51:09.000Z - 24 days ago

AstraZeneca's (AZN) Calquence Gains FDA Approval for Leukemia Treatment

FDA Approves AstraZeneca's Calquence Plus Venetoclax For Chronic Lymphocytic Leukemia

2026-02-20T08:00:00.000Z - 24 days ago

FDA Approves AstraZeneca's Calquence Plus Venetoclax For Chronic Lymphocytic Leukemia

AstraZeneca (AZN) Strikes Major Licensing Deal in China

2026-02-19T18:59:54.000Z - 24 days ago

AstraZeneca (AZN) Strikes Major Licensing Deal in China

EMA Validates Enhertu Application for AstraZeneca (AZN)

2026-02-19T10:25:39.000Z - 25 days ago

EMA Validates Enhertu Application for AstraZeneca (AZN)

Daiichi Sankyo: ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

2026-02-19T07:36:00.000Z - 25 days ago

Daiichi Sankyo: ENHERTU Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)

2026-02-18T22:53:04.000Z - 25 days ago

FDA Implements New Policy for Drug Approval Requirements Impacting AstraZeneca (AZN)

FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals

2026-02-18T22:52:10.000Z - 25 days ago

FDA Policy Shift: Impact on AstraZeneca (AZN) and Pharmaceuticals

AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development

2026-02-18T15:58:39.000Z - 26 days ago

AstraZeneca (AZN) Partners with Evinova for AI-Driven Drug Development

Top 3 Health Care Stocks That May Collapse This Quarter

Wed, 18 Feb 2026 09:04:08 -0500 - 26 days ago

Top 3 Health Care Stocks That May Collapse This Quarter

Apple, Ulta Beauty, AstraZeneca And A Real Estate Stock On CNBC's 'Final Trades'

2026-02-18T13:47:46.000Z - 26 days ago

Apple, Ulta Beauty, AstraZeneca And A Real Estate Stock On CNBC's 'Final Trades'

Impax International Sustainable Economy Fund Q4 2025 Contributors And Detractors

Wed, 18 Feb 2026 08:47:00 -0500 - 26 days ago

Impax International Sustainable Economy Fund Q4 2025 Contributors And Detractors

Final Trades: Apple, AstraZeneca, Vici Properties and Ulta Beauty

2026-02-17T18:17:14.000Z - 26 days ago

Final Trades: Apple, AstraZeneca, Vici Properties and Ulta Beauty

AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results in Asthma Trials

2026-02-13T12:30:19.000Z - 4 weeks ago

AstraZeneca's (AZN) Breztri Aerosphere Shows Promising Results in Asthma Trials

China charges former AstraZeneca executive – what it means for global pharmaceutical firms

2026-02-13T12:00:12.000Z - 4 weeks ago

China charges former AstraZeneca executive – what it means for global pharmaceutical firms

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

2026-02-12T18:26:00.000Z - 4 weeks ago

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca

2026-02-12T11:50:42.000Z - 4 weeks ago

Big Deal, Bigger Doubts: CSPC Slides After $18.5B Pact With AstraZeneca

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

Feb 11, 2026, 9:00 AM EST - 4 weeks ago

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy

Feb 10, 2026, 3:43 PM EST - 4 weeks ago

AstraZeneca: Q4 Earnings Analysis - Ticks The Boxes, Upgrading To Buy

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript

Feb 10, 2026, 12:44 PM EST - 4 weeks ago

AstraZeneca PLC (AZN) Q4 2025 Earnings Call Transcript

AstraZeneca results: FY and Q4 2025

Feb 10, 2026, 7:00 AM EST - 4 weeks ago

AstraZeneca results: FY and Q4 2025

AstraZeneca Forecasts Continued Growth on Pipeline Strength

Feb 10, 2026, 2:34 AM EST - 4 weeks ago

AstraZeneca Forecasts Continued Growth on Pipeline Strength

AstraZeneca profit climbs on cancer and heart drug demand

Feb 10, 2026, 2:24 AM EST - 4 weeks ago

AstraZeneca profit climbs on cancer and heart drug demand

Drugmaker AstraZeneca forecasts sales and profit growth in 2026

Feb 10, 2026, 2:06 AM EST - 4 weeks ago

Drugmaker AstraZeneca forecasts sales and profit growth in 2026

Oakmark International Strategy Q4 2025 New Investments And Divestments

Feb 8, 2026, 12:20 PM EST - 5 weeks ago

Oakmark International Strategy Q4 2025 New Investments And Divestments

NVS SNY UL

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

Feb 3, 2026, 2:42 AM EST - 5 weeks ago

AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

Feb 3, 2026, 2:18 AM EST - 5 weeks ago

US FDA rejects AstraZeneca's easier-to-use version of lupus therapy

AstraZeneca begins trading on the New York Stock Exchange

Feb 2, 2026, 7:00 AM EST - 6 weeks ago

AstraZeneca begins trading on the New York Stock Exchange

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

Feb 1, 2026, 2:49 AM EST - 6 weeks ago

AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

Jan 30, 2026, 2:51 AM EST - 6 weeks ago

AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

Jan 30, 2026, 2:15 AM EST - 6 weeks ago

World leaders descend on Beijing as 2026 kicks off, hedging against U.S. disruptions

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

Jan 29, 2026, 8:35 PM EST - 6 weeks ago

China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy

AstraZeneca sets out $15 billion China investment during Starmer visit

Jan 29, 2026, 5:00 AM EST - 6 weeks ago

AstraZeneca sets out $15 billion China investment during Starmer visit

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

Jan 28, 2026, 4:01 PM EST - 6 weeks ago

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip

Jan 27, 2026, 10:59 PM EST - 6 weeks ago

Airbus, AstraZeneca and HSBC executives join UK's Starmer on high-stakes China trip

HSBC

Astrazeneca CEO Soriot to join Starmer delegation to China, source says

Jan 26, 2026, 7:55 AM EST - 7 weeks ago

Astrazeneca CEO Soriot to join Starmer delegation to China, source says

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

Jan 20, 2026, 11:47 AM EST - 7 weeks ago

AstraZeneca To Delist ADRs From Nasdaq By January, Eyes Broader Investor Reach

AstraZeneca to delist from Nasdaq, join NYSE in February

Jan 20, 2026, 2:21 AM EST - 7 weeks ago

AstraZeneca to delist from Nasdaq, join NYSE in February

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Jan 15, 2026, 11:35 AM EST - 2 months ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

GEHC LLY

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 4:15 PM EST - 2 months ago

AstraZeneca PLC (AZN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AstraZeneca to acquire Modella AI to speed oncology drug research

Jan 13, 2026, 12:10 PM EST - 2 months ago

AstraZeneca to acquire Modella AI to speed oncology drug research

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

Jan 13, 2026, 12:02 PM EST - 2 months ago

Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Jan 10, 2026, 10:00 AM EST - 2 months ago

AstraZeneca: Oncology Dominance Justifies New All-Time Highs

Healthy Returns: What to expect from pharma at the JPM conference

Jan 9, 2026, 12:57 PM EST - 2 months ago

Healthy Returns: What to expect from pharma at the JPM conference

AMGN BMY LLY MRK NVO PFE

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Jan 8, 2026, 7:12 AM EST - 2 months ago

AstraZeneca names Rick Suarez head of US biopharmaceuticals unit

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

Jan 8, 2026, 7:00 AM EST - 2 months ago

Rick R. Suarez appointed US President and Head of US BioPharmaceuticals Business Unit

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

Jan 6, 2026, 7:44 AM EST - 2 months ago

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

Jan 2, 2026, 1:55 PM EST - 2 months ago

These Healthcare and Bank Stocks Had Incredible Runs in 2025. Why Gains Will Continue This Year.

BK C CAH CVS

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

Dec 22, 2025, 2:39 AM EST - 3 months ago

AstraZeneca Drug Combination Falls Short of Goal in Lung-Cancer Trial

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

Dec 22, 2025, 2:22 AM EST - 3 months ago

AstraZeneca's ceralasertib-Imfinzi combo misses survival target in lung cancer trial

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

Dec 19, 2025, 6:25 PM EST - 3 months ago

This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter

ALNY AMGN ARGX IBB

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 3 months ago

Trump to announce new drug-pricing deals later today

ABBV AMGN BMY GILD LLY MRK NVO

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

Dec 19, 2025, 2:30 AM EST - 3 months ago

AstraZeneca: Mispriced Growth Following The Oncology Segment Success

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 3 months ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN BMY LLY NVS PFE

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

Dec 15, 2025, 4:29 PM EST - 3 months ago

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

Dec 10, 2025, 10:26 AM EST - 3 months ago

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Dec 8, 2025, 8:10 AM EST - 3 months ago

BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

Dec 4, 2025, 4:00 PM EST - 3 months ago

Salesforce's Agentforce Life Sciences Selected by AstraZeneca as Its Unified Global Platform to Help Transform Customer Engagement

CRM

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

Dec 4, 2025, 7:00 AM EST - 3 months ago

AstraZeneca advances hematology and cell therapy ambition with largest-ever presence at ASH

ZacksResearch
ZacksResearch Mar. 16 at 2:58 PM
$LLY could reportedly re-enter the bidding race for $ABVX if $AZN fails to submit an acquisition offer before the March 23 exclusivity deadline 👀 Reports indicate AstraZeneca currently has exclusive access to Abivax’s data room as it evaluates a potential takeover of the French biotech, whose shares skyrocketed last year after strong Phase 3 data for ulcerative colitis drug candidate obefazimod. If the exclusivity window closes without a bid, Lilly could re-engage as Big Pharma continues hunting for late-stage pipeline assets 💊 📊 Price target breakdown here👇 https://www.zacks.com/stock/research/LLY/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-37316&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_37316
0 · Reply
briefingcom
briefingcom Mar. 16 at 12:35 PM
$AZN: AstraZeneca receives EU approval for Imfinzi in early gastric and gastroesophageal cancers https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260316042755AZN&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Quantumup
Quantumup Mar. 16 at 11:16 AM
Jefferies🏁 $ABVX at a Buy rating and a $160 PT. $AZN $LLY ABBV PFE $PTGX - $JNJ Jefferies said in its initiation report: Obe already looks like a real and differentiated UC drug, and we think the 2Q26 maintenance readout is fairly de-risked and should provide clear path to approval. We also think Crohn's matters for the long-term valuation (and hence any potl strategic interest). We are more bullish vs buyside expectations and see a strong shot based on MOA, translational data, and precedent. Bottom line: ABVX still underappreciated relative to the robust UC story and CD upside.
0 · Reply
Quantumup
Quantumup Mar. 13 at 3:09 PM
BofA⬆️ Mineralys' PT to $51 from $46 and reiterated at a Buy, separately Stifel on $MLYS said: We reiterate our Buy rating, $52 TP. $AZN $ALNY - $RHHBY $NVS Here's what else Stifel had to say: https://x.com/Quantumup1/status/2032473479035936901?s=20
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:37 PM
$AZN take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
Chipwars
Chipwars Mar. 12 at 3:50 PM
$AZN AstraZeneca (AZN) Refutes Takeover Speculation https://www.gurufocus.com/news/8703449/astrazeneca-azn-refutes-takeover-speculation
0 · Reply
Quantumup
Quantumup Mar. 12 at 2:55 PM
Cantor reiterated $CMPX at an Overweight rating, and said: In April, we expect the long-awaited PFS/OS readout from the Phase 2/3 COMPANION-002 trial of tovecimig (DLL4 x VEGF-A) in second-line biliary tract cancer (BTC). $AZN $MRK PFE RLAY Cantor added—This represents a high-stakes readout for Compass and one we view with cautious optimism. In this note, we walk through trial background, expectations for PFS and OS, potential stock scenarios, and key risks. We believe the trial is highly likely to achieve statistical significance on PFS, broadly in line with investor expectations. The core debate centers on overall survival (OS) and whether the study will clear the statistical threshold on this secondary endpoint. Given that ~80% OS events were triggered in 1Q26, in-line with our assumptions in our initiation report, we maintain our ~50% probability of success for OS.
0 · Reply
Chipwars
Chipwars Mar. 12 at 2:30 PM
$AZN AstraZeneca ranks among the 14 safe stocks to buy now for a starter stock portfolio. https://finance.yahoo.com/news/morgan-stanley-sees-double-digit-063059179.html
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 12 at 12:33 PM
$ABVX (+9.3% pre) The French start-up led by Marc de Garidel is giving the British pharma giant $AZN exclusive access to its data until 23 March to help it decide on its takeover bid. If it fails to make a bid by that date, Abivax will be free to negotiate with other potential buyers. - La Lettre https://ooc.bz/l/96438
1 · Reply
notreload_ai
notreload_ai Mar. 12 at 11:42 AM
$ABVX , $AZN, $LLY ... AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise. https://notreload.xyz/astrazeneca-leads-abivax-takeover-talks-until-march-23/
0 · Reply
DonCorleone77
DonCorleone77 Mar. 12 at 10:45 AM
$ABVX $AZN AstraZeneca granted exclusive period by Abivax for buyout, La Lettre reports Abivax (ABVX) has granted AstraZeneca (AZN) an exclusive period through March 23 to access confidential information and formalize a potential takeover offer, La Lettre's Matthew Protard reports. After that date, Abivax may reopen discussions with other interested bidders if no deal is reached, Protard writes.
1 · Reply
wwmeinc
wwmeinc Mar. 11 at 3:26 PM
$VKTX $AZN ....How very true...truth in data release is the only way...'massaging the message' serves nobody interest except those afraid of the reaction :) glta https://www.fiercebiotech.com/biotech/astrazeneca-reveals-oral-glp1-scored-phase-2-wins-holds-back-weight-loss-data
0 · Reply
neo55
neo55 Mar. 10 at 8:49 PM
$IPHA Innate Pharma, the 2026 readout If PACIFIC-9 succeeds: • potential $500M+ milestone payments • long-term double-digit royalties 2-5 billion deals with $AZN 1-2 billion deal with $BMY 1-2 billion deal with $NVO Can 10 x overnight do research
0 · Reply
Quantumup
Quantumup Mar. 10 at 1:27 PM
Needham⬆️the PT on $CELC to $122 from $95 and reiterated at a Buy $RLAY $RHHBY LLY $AZN $NVS PFE Needham said—Celcuity announced yesterday that the NDA for gedatolisib received priority review, with a PDUFA date of July 17, 2026. Additionally, the company announced the publication of results from the PIK3CA WT cohort of the VIKTORIA-1 study evaluating gedatolisib-based regimens in HR+/HER2- mBC in the Journal of Clinical Oncology. The detailed results were consistent with prior disclosures, while demonstrating a trending benefit in OS. Given the potential for an earlier approval, we reiterate our Buy Rating and are increasing our Price Target from $95 to $122.
0 · Reply
RobotMumba100
RobotMumba100 Mar. 9 at 5:45 PM
$TEM free money here... this is the new $PLTR in pharma sector... 100$ end of the year! $MRK $AZN
0 · Reply
IndyOne
IndyOne Mar. 9 at 2:17 PM
$MRNA October 2025: STET rumored Moderna "deal of significant scope" in discussion, buyout or massive partnership. December 2025: Stéphane Bancel and his wife, Moderna CEO, sold his six-level home in Boston where he has lived for +12 years. January 2026: Moderna and Merck announced five-year follow-up data from the Phase 2b KEYNOTE-942 trial showed a 49% reduction in the risk of recurrence or death. Keytruda goes off patent soon, Merck can use Moderna's mRNA-4157 (also known as V940 or intismeran autogene) a first-of-its-kind, personalized mRNA cancer vaccine to extend Keytruda protection. February 2026: Patent litigation resolved with payment from Moderna. Moderna wanted the decks clear, they could have fought this longer like Pfizer & Biontech. NO ROYALTIES! HUGE WIN. News coming. Big. Could involve $JNJ $MRK $RHHBY $AZN
0 · Reply
Chipwars
Chipwars Mar. 6 at 4:44 PM
$AZN Jefferies has lifted its price target on AstraZeneca PLC, the FTSE 100 pharmaceutical company, from 15,000p to 18,000p, reiterating a 'buy' recommendation, arguing that the drugmaker is better positioned for long-term growth than the market appreciates. https://www.proactiveinvestors.co.uk/companies/news/1088472/jefferies-raises-astrazeneca-target-to-18-000p-as-analysts-flip-view-on-delayed-cancer-trial-1088472.html
0 · Reply
JuanValdex
JuanValdex Mar. 6 at 4:13 PM
$BFRG $AZN If the next generation of americans are pussies, (like the brits) , and we see a market down turn,,,, will they flock to nerdish stocks like BIO-tech,,, creating a possible mania?
0 · Reply
JuanValdex
JuanValdex Mar. 6 at 3:33 PM
$BFRG $DAWN $AZN
0 · Reply
JuanValdex
JuanValdex Mar. 6 at 2:46 PM
$AZN What did you guys pay for Modello $DAWN $BFRG
1 · Reply
JFais
JFais Mar. 4 at 7:56 PM
$IOVA- still top position @ 14% PW. IF margins really do trend toward 70%, entrenched ATC network will be a significant differentiator with high strategic value to acquirer (pharma with a large IO presence a la $MRK $BMY $AZN)
1 · Reply
TheLionofwallstreet
TheLionofwallstreet Mar. 4 at 5:50 PM
$AIM $AZN Sees they aim didn’t raise enough cash... they see the results and an opertunity for a cheap buyout. They could just fund Aim with their budget but why when they could buy it for penuts with aims back against the wall. Easy play.
0 · Reply